Gemzar

Gemzar is a brand name of gemcitabine, approved by the FDA in the following formulation(s):

GEMZAR (gemcitabine hydrochloride - injectable; injection)

• 
  Manufacturer: LILLY
  
  Approval date: May 15, 1996
  
  Strength(s): EQ 1GM BASE/VIAL ^[RLD][AP], EQ 200MG BASE/VIAL ^[RLD][AP]

Has a generic version of Gemzar been approved?

A generic version of Gemzar has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Gemzar and have been approved by the FDA:

gemcitabine hydrochloride injectable; injection

• 
  Manufacturer: ACCORD HLTHCARE
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: ACTAVIS TOTOWA
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: FRESENIUS KABI ONCOL
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: HOSPIRA
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: ONCO THERAPIES LTD
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: SUN PHARMA GLOBAL
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: TEVA PARENTERAL
  
  Approval date: January 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]


• 
  Manufacturer: WATSON LABS
  
  Approval date: July 25, 2011
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 200MG BASE/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gemzar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of treating tumors in mammals with 2',2'-difluoronucleosides
  Patent 5,464,826
  Issued: November 7, 1995
  Inventor(s): Grindey; Gerald B. & Hertel; Larry W.
  Assignee(s): Eli Lilly and Company
  A method of treating susceptible neoplasms in mammals comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of the formula ##STR1## wherein: R.sup.1 is hydrogen; R.sup.2 is a base defined by one of the formulae ##STR2## X is C-R.sup.4 ; R.sup.3 is hydrogen; R.sup.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, bromo, fluoro, chloro or iodo; and the pharmaceutically-acceptable salts thereof.
  
  Patent expiration dates:
  
  
  • November 7, 2012
    
    ✓ 
    Patent use: METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
  
  
  
  • May 7, 2013
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Gemzar Consumer Information (Drugs.com)
• Gemzar Consumer Information (Wolters Kluwer)
• Gemzar Consumer Information (Cerner Multum)
• Gemzar Advanced Consumer Information (Micromedex)
• Gemzar AHFS DI Monographs (ASHP)
• Gemcitabine Consumer Information (Wolters Kluwer)
• Gemcitabine Consumer Information (Cerner Multum)
• Gemcitabine Intravenous Advanced Consumer Information (Micromedex)
• Gemcitabine Hydrochloride AHFS DI Monographs (ASHP)